Android Apple

Novo, Catalent's $16.5B Deal for Weight-Loss Drug Production Gets European Commission Approval

By MarketWatch   |   2 weeks ago
Novo, Catalent's $16.5B Deal for Weight-Loss Drug Production Gets European Commission Approval

The European Commission approved Novo Holdings' acquisition of Catalent, expected to close by year-end. Novo will acquire Catalent for $16.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.